Account
Watchlists
Bookmarks
Pricing
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2025
No. of Analysts
1Y Price Target
Q3 EPS Estimate
Q3 Revenue Estimate
Price, EPS and Revenue Projections
Strong Buy
4
Buy
5
Hold
1
Sell
0
Strong Sell
0
updated on
Dec 03, 2025
Bearish
4
Neutral
6
Bullish
4
Bearish
22
Neutral
6
Bullish
18
Bearish
18
Neutral
0
Bullish
14
Get In-depth insights on EPS and Revenue forecasts
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q3 FY25
Senores Pharmaceuticals Limited is a global pharmaceutical company focused on developing and manufacturing a wide range of pharmaceutical products for regulated markets, particularly in the US, Canada, and the UK.
The company achieved a 61% increase in revenue in Q2FY26 and grew its profit after tax by 131% year-on-year, demonstrating strong financial performance and growth momentum.
With 81 ANDA products and successful launches in the CDMO-CMO segment, Senores is well-positioned in regulated and emerging markets, indicating a robust pipeline for future growth.
Senores is undertaking significant capacity expansion at its US facility, scheduled to reach an annual installed capacity of 2 billion units, which will cater to its expanding portfolio and support sustained growth.
Pharmaceuticals
Pharmaceuticals - Indian - Formulations
3,756 Cr
High Risk
43.1
43.8
1.4
4.6
847.90
440.00
Sales CAGR
1Y
85.65%
3Y
41.70%
5Y
—
10Y
—
Profit CAGR
1Y
78.36%
3Y
75.57%
5Y
—
10Y
—
ROE
TTM
10.70%
3Y
0.62%
5Y
0.75%
10Y
—
ROCE
TTM
12.41%
3Y
1.94%
5Y
2.02%
10Y
—
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Performance
STEADY PERFORMER
Valuation
OVERVALUED
Growth
EXCEPTIONAL
Profitability
MODERATE MARGIN
Technicals
Bearish
Risk
HIGH RISK
Market Cap
₹ 3,756 Cr
P/E
43.11
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
132.80 | 4,423 Cr | — | 0.00 | 0.00 | 77.47 | -181.73 | -82.81 | |
819.30 | 3,756 Cr | 43.11 | 4.61 | 0.00 | 10.70 | 12.41 | 6.65 | |
56.39 | 2,352 Cr | 198.93 | 35.74 | 0.02 | 18.17 | 20.39 | 13.71 | |
680.00 | 1,942 Cr | 34.26 | 5.68 | 0.68 | 16.57 | 22.53 | 13.11 | |
776.00 | 1,647 Cr | 24.47 | 3.08 | 0.74 | 12.60 | 16.43 | 8.27 | |
143.80 | 1,510 Cr | 13.78 | 1.33 | 0.35 | 9.68 | 14.69 | 8.24 | |
14.82 | 1,412 Cr | 22.42 | 3.73 | 0.00 | 16.66 | 22.00 | 13.82 |
Investor Meeting Outcome
4 hours ago
Outcome of Analyst/Investor Meet
Senores Pharmaceuticals Limited announced the completion of a Business Update Call with analysts and investors on December 16, 2025, and shared the audio recording of the meeting.
Analyst/Investor Meet
1 day ago
Business Update Call Announcement
Senores Pharmaceuticals Limited has scheduled a Business Update Call for investors on December 16, 2025, at 11:00 A.M. (IST).
Investor Presentation
1 day ago
Senores Pharmaceuticals to Acquire Apnar Pharma
Senores Pharmaceuticals Limited announced a business update regarding the acquisition of Apnar Pharma Private Limited, enhancing its market capabilities and manufacturing capacity.
Acquisition Announcement
1 day ago
Senores Pharmaceuticals Acquires Apnar Pharma
Senores Pharmaceuticals Limited has entered into a Share Purchase Agreement to acquire 100% of Apnar Pharma Private Limited, making it a wholly owned subsidiary.
Press Release
4 days ago
Launch of Deferiprone Tablets by Senores Pharmaceuticals
Senores Pharmaceuticals, Inc. announced the approval and launch of Deferiprone Tablets USP, 500 mg & 1000 mg, to be marketed by Dr. Reddy's Laboratories in the US market.
